anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Neumora Therapeutics · pitchdeck

Neumora Therapeutics | IPO Presentation Deck | 32 slides

32 pages · 5 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Neumora Therapeutics | IPO Presentation Deck | 32 slides

Neumora Therapeutics · 2023-09
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 12 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Setup 5 slides 100% 5/5 slides 100% 5/5 slides · 22 hits
— 0/5 slides
— 0/5 slides
— 0/5 slides
100% 5/5 slides
— 0/5 slides
Complication 2 slides 100% 2/2 slides 100% 2/2 slides · 13 hits
— 0/2 slides
50% 1/2 slides 50% 1/2 slides 100% 2/2 slides · 3 hits 100% 2/2 slides · 3 hits Evidence 3 slides 100% 3/3 slides 100% 3/3 slides · 11 hits
— 0/3 slides
66.7% 2/3 slides
— 0/3 slides
100% 3/3 slides · 4 hits 100% 3/3 slides · 4 hits Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides
— 0/1 slides

Slide inventory

32
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Setup
02
other
Open slide detailBeat · Setup
03
summarize
Open slide detailBeat · Setup
04
inspire_vision
Open slide detailBeat · Setup
05
summarize
Open slide detailBeat · Setup
06
The slide is split into two sections: Leadership (with headshots and bios) and Blue Chip Investors (with logos).other
Open slide detail
07
The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.plan_implementation
Open slide detail
08
Includes a detailed biological mechanism diagram showing the interaction of KOR, dynorphin, and neurotransmitters.present_solution
Open slide detailBeat · Solution
09
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.establish_context
Open slide detailBeat · ComplicationLoop · Cost Of Inaction
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).show_traction
Open slide detailBeat · ComplicationLoop · Cost Of Inaction
11
The table displays statistical significance (p-values) for multiple clinical endpoints.show_traction
Open slide detailBeat · EvidenceLoop · Jobs To Be Done
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).show_traction
Open slide detailBeat · EvidenceLoop · Jobs To Be Done
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.present_framework
Open slide detail
14
The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).compare_peers
Open slide detail
15
Includes qualitative expert testimonials regarding pricing and market access.size_opportunity
Open slide detailBeat · Market Sizing
16
The diagram illustrates a decision-tree process based on clinical trial outcomes.plan_implementation
Open slide detail
17
Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.present_solution
Open slide detail
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.show_traction
Open slide detail
19
The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.present_solution
Open slide detail
20
The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.compare_peers
Open slide detail
21
The slide uses a biological pathway diagram to illustrate the mechanism of action (PAM) and the pathology of schizophrenia.present_solution
Open slide detail
22
Includes a biological mechanism diagram showing the inhibition of TDP-43 phosphorylation by NMRA-CK1δ.present_solution
Open slide detail
23
MVAE stands for Multimodal Variational Autoencoder.present_solution
Open slide detail
24
The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.present_solution
Open slide detail
25
Includes a detailed biological pathway diagram illustrating the mechanism of action.present_solution
Open slide detail
26
The slide uses a linear process flow (Challenge -> Toolbox -> Value) to explain the company's methodology.present_solution
Open slide detail
27
summarize
Open slide detail
28
plan_implementation
Open slide detail
29
appendix
Open slide detail
30
The slide uses a table to demonstrate IP defensibility and a green footer section to categorize the IP strategy.other
Open slide detail
31
Clinical trial baseline characteristics table.analyze_data
Open slide detail
32
The slide uses two line charts to visualize clinical trial data with p-values and delta LSM values.show_traction
Open slide detail